Prognostic significance of miR-126 in various cancers: a meta-analysis
Authors Dong Y, Fu C, Guan S, Zhang Z, Zhou T, Li B
Received 1 January 2016
Accepted for publication 1 February 2016
Published 28 April 2016 Volume 2016:9 Pages 2547—2555
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 2
Editor who approved publication: Dr William Cho
Yuanli Dong,1,2 Chengrui Fu,2 Hui Guan,2 Zicheng Zhang,2 Tao Zhou,2 Baosheng Li2
1School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences, Jinan, Shandong Province, 2Sixth Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, Shandong Province, People’s Republic of China
Objective: Recent studies have demonstrated that microRNA-126 (miR-126) might be a promising prognostic factor for cancer patients. This meta-analysis was conducted to assess the effectiveness of miR-126 as a prognostic biomarker for various cancers.
Methods: The search of studies was performed by using PubMed and Embase until January 22, 2016. Pooled hazard ratio (HR) with 95% confidence interval (CI) for patients’ survival was calculated. A fixed-effect or random-effects model was applied according to heterogeneity. The trim and fill method was used to adjust pooled HR.
Results: In all 17 articles comprising of 2,437 participants were included in this meta-analysis. The results indicated that a high level of miR-126 played a favorable role in the overall survival (HR 0.70, 95% CI: 0.62–0.79, random-effects model), with a heterogeneity measure index of I2=63.2% (P<0.01). Subgroup analyses showed that pooled HR was more significant in patients with digestive system cancers (HR 0.70, 95% CI: 0.59–0.83, fixed-effects model) and respiratory system cancers (HR 0.71, 95% CI: 0.59–0.85, random-effects model). Owing to publication bias, HR was adjusted to 0.59 (0.463–0.752, P<0.01) by the trim and fill method.
Conclusion: miR-126 could be a promising biomarker for cancer prognosis prediction, especially in patients with digestive or respiratory system cancers.
Keywords: cancer, miR-126, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]